Subject noncompliance in clinical trials ranges from 20% to 80%, depending on the therapeutic area. This is due to a number of factors, including subjects failing to follow medication regimes, missing clinical visits, and failing to comply with crucial requirements of the study. Replacing noncompliant subjects can have a significant impact on cost, recruitment, timelines, and the data quality of a clinical study. As a result, overcoming subject noncompliance is an increasingly important issue in the pharmaceutical industry.